Choosing a medication-assisted treatment program is one of the most consequential decisions you’ll make in recovery, and most people make it without knowing what to actually look for. This guide gives you the criteria to evaluate any program clearly, so you can ask the right questions before you commit.
What Medication-Assisted Treatment Actually Is
A 2020 Cochrane Review analyzing data from over 31,000 patients found that medication-assisted treatment reduces opioid use, overdose deaths, and criminal activity more effectively than abstinence-only approaches across every outcome measured. That is not a marginal finding. It is the clinical standard.
MAT combines FDA-approved medications with behavioral therapy and counseling to treat substance use disorders, primarily opioid use disorder and alcohol use disorder. The medications work by targeting the same brain receptors that drugs and alcohol affect, either blocking the euphoric effect, reducing cravings, or managing withdrawal symptoms. What separates MAT from simply prescribing medication is the surrounding structure: medical oversight, therapy, and a treatment plan that addresses the whole person.
The concrete takeaway here is this: if a program frames MAT as a shortcut or a “lesser” form of recovery, that program is behind the evidence. Medication is a clinical tool. Evaluating it as one is where your search should start.
The Medications Used in MAT Programs (and What They Treat)
A 2021 study published in the New England Journal of Medicine comparing MAT medications found that all three FDA-approved opioid medications significantly outperformed placebo in reducing illicit opioid use, but that individual patient factors drove which medication produced the best retention. Matching medication to patient history is not a formality. It is the clinical work itself.
Opioid Use Disorder: Buprenorphine, Methadone, and Naltrexone
Buprenorphine, often dispensed as Suboxone, is a partial opioid agonist. It activates opioid receptors just enough to prevent withdrawal and reduce cravings without producing significant euphoria at therapeutic doses. It can be prescribed in an office-based setting by a DATA-waivered physician, which makes it more accessible than methadone. For those beginning buprenorphine induction, the first days of treatment involve careful dose calibration to stabilize the patient.
Methadone is a full opioid agonist dispensed daily at licensed clinics under direct supervision. It carries a higher level of structure and is typically reserved for patients with longer histories of dependence or who haven’t responded to buprenorphine.
Naltrexone, available as an extended-release injectable under the brand name Vivitrol, works differently from both. It is an opioid antagonist that blocks receptors entirely, producing no euphoric effect and no physical dependence. A 2018 study in The Lancet comparing buprenorphine and extended-release naltrexone found comparable outcomes once patients were fully detoxed, with naltrexone performing particularly well for motivated patients with strong support systems. The question to ask any program: which of these do you offer, and why does your clinical team recommend one over the others for someone in my specific situation?
Alcohol Use Disorder: What the Evidence Supports
For alcohol use disorder, the two primary medications are naltrexone and acamprosate. Naltrexone reduces the craving to drink by blocking the reward response alcohol produces in the brain. A 2014 meta-analysis published in JAMA covering 122 randomized trials found naltrexone reduced return-to-heavy-drinking by 83% compared to placebo. Acamprosate works differently, stabilizing the neurochemical disruption that persists after detox, which is the post-acute withdrawal period that drives relapse weeks or months into recovery.
Programs that don’t discuss medication options for alcohol use disorder are not meeting the current standard of care. That is not an opinion. It is what the clinical literature supports.
Key Factors to Evaluate When Choosing a MAT Program
A 2019 study from the National Institute on Drug Abuse following 1,200 patients across 11 treatment sites found that treatment matching, aligning the intensity and type of care with individual need, predicted 90-day retention better than any single medication or therapy modality. For a MAT program addressing opioid addiction, the specific factors below separate programs that produce results from those that produce paperwork.
Medical Supervision and Prescriber Credentials
Look for board-certified addiction medicine physicians, DATA-waivered prescribers for buprenorphine, and 24/7 medical access during the acute phase. A 2017 analysis from SAMHSA found that physician-led MAT programs showed 40% higher one-year retention rates compared to programs where prescribing was managed without addiction medicine oversight. Who writes the prescription and who monitors your response to it matters as much as which medication is selected.
Ask directly: is a physician involved in my care daily, or only at intake and monthly check-ins?
Dual Diagnosis Treatment Capacity
A 2021 report from the Substance Abuse and Mental Health Services Administration found that 9.2 million adults in the U.S. met criteria for both a substance use disorder and a co-occurring mental health condition in the prior year. Depression, anxiety, PTSD, and bipolar disorder are not background noise in addiction treatment. They are frequently the conditions driving substance use in the first place.
Programs that treat addiction without licensed mental health clinicians on staff, not on referral, but present and integrated, produce worse outcomes for this population. Ask any program you’re evaluating whether psychiatric and psychological services are provided in-house or contracted out. The answer tells you a great deal.
Length and Continuity of Treatment
NIDA’s research consensus holds that treatment lasting fewer than 90 days produces limited outcomes for most patients with moderate-to-severe substance use disorders. Short detox programs that do not include a continuation plan for MAT after discharge have the highest relapse rates. The mechanism is straightforward: detox clears the substance, but it does not restructure the neurological patterns or address the behavioral and psychological factors that sustained the addiction.
Ask every program you speak with how they handle the transition from inpatient or residential care to outpatient MAT, and what the first 90 days after discharge looks like in concrete terms.
Questions to Ask Before You Enroll
A 2016 study from the Journal of Substance Abuse Treatment tracking 800 patients found that those who asked specific questions about their treatment plan during intake had 28% higher 6-month treatment retention than those who did not. Patient-provider communication is not a soft variable. It predicts outcomes.
Write these five questions down before the first call: Which medications do you offer, and why would you recommend one over another for my situation? Do you have licensed mental health clinicians on staff? What does the transition from inpatient to outpatient look like? What is your discharge plan, and what happens if I relapse after leaving? What is the full cost, and what does that include? A program that can’t answer these clearly and specifically on the first call is telling you something important.
Private Pay vs. Insurance-Covered MAT: What to Know
A 2023 analysis from the Kaiser Family Foundation found that private-pay addiction treatment programs carry per-day costs ranging from two to four times those of insurance-contracted programs, but typically offer lower patient-to-staff ratios, faster admission timelines, and more individualized clinical programming. For patients who can fund care directly, the trade-off is real.
When you’re evaluating cost, ask for a full itemized breakdown of what the program fee actually covers: medications, medical appointments, psychiatric services, therapy sessions, drug testing, and discharge planning. Programs that quote a single number without detail often have significant out-of-pocket costs embedded. Understanding what medication management looks like across the full length of treatment helps you ask the right financial questions before signing anything.
Red Flags That Rule Out a Program
A 2020 Government Accountability Office report examining low-quality addiction treatment facilities identified several consistent patterns in programs with the worst outcomes: absence of licensed medical staff, refusal to discuss medication options, and vague or non-existent discharge planning.
Specifically, walk away from any program that has no physician on staff, that presents abstinence-only ideology as clinical fact rather than one valid pathway, that offers no mental health services, or that pressures you to decide before you’ve had time to review the answers to your core questions. A credible program welcomes your questions. It doesn’t rush you past them.
How MAT Fits Into a Full Continuum of Care
A 2019 study in Drug and Alcohol Dependence following 600 patients over two years found that patients who received MAT combined with cognitive behavioral therapy maintained sobriety at twice the rate of those who received medication alone. Medication addresses the neurological dimension of addiction. Behavioral therapy addresses the cognitive and emotional patterns. Neither is sufficient on its own.
The continuum looks like this in practice: medically supervised detox, followed by residential or partial hospitalization, then intensive outpatient, then outpatient MAT with ongoing therapy, then aftercare and community support. At Soul Detox, MAT is integrated within medically supervised detox and carried forward as one component of a larger treatment architecture, paired with mental health support and structured around the individual’s clinical picture, not a protocol applied uniformly. For those exploring options in Southern California, understanding how a program structures this full continuum is a better predictor of outcomes than any single feature.
Ask any program to walk you through every transition point, what the criteria are for moving from one level to the next, and who is responsible for that decision.
Where to Start This Week
Identify two or three programs that meet the criteria covered here. Then call them with the five questions listed above and compare their answers side by side. You already have what you need to evaluate the responses. A program that offers clear, specific answers, describes a real continuum, employs licensed clinicians on staff, and can explain its medication approach in plain language is the one worth a second conversation.